All News

RheumNow Podcast square

Rheum Chapter Notes (4.26.2024)

Jack Cush, MD

Dr. Jack Cush reviews this past week’s news and journal articles from RheumNow.com.

Read Article
bone.infection.gram_.rod_.jpg

Predicting Infection in Lupus Nephritis

Jack Cush, MD

Machine learning (ML) models were applied to 3 cohorts of lupus nephritis (LN) patients and established algorithms to predict co-infection in LN. 

Read Article
DPGN, lupus, nephritis, GN, glomerulonephritis, biopsy, kidney

Predicting CKD Outcomes in Lupus Nephritis

Jack Cush, MD

An observational cohort study suggests that proteinuria levels in lupus nephritis (LN) patients did not predict their histologic class.

A multicentre observational study of patients with biopsy-proven LN; either proliferative (PLN) or membranous (MLN) lupus nephritis were compared regarding clinical and laboratory presentation and long-term outcomes. The primary outcome was progression to chronic kidney disease (CKD).

Read Article
FDAmeeting.jpg

Lupus Accelerating Breakthroughs Consortium Partners with FDA

EurekAlert!

The Lupus Research Alliance (LRA), founder and administrator of the Lupus Accelerating Breakthroughs Consortium (Lupus ABC), announced today at the Consortium’s first anniversary meeting an expanded partnership with the U.S.

Read Article
RheumNow Podcast square

Burnout or Retire (4.12.2024)

Jack Cush, MD

Dr. Jack Cush reviews the news and journal reports from this past week on RheumNow.com. Is it time to worry about burnout and those who are leaving healthcare?

Read Article
brain headache neuro

Neuropsychiatric SLE - 2/3 Improved at 12 Months

Jack Cush, MD

The management and outcomes of neuropsychiatric systemic lupus erythematosus (NPSLE) can be challenging as there is limited data. 

Read Article
Malar,rash,SLE, Lupus

JAMA: SLE Review

Jack Cush, MD

Drs. Caroline Siegel and Lisa Sammaritano (from HSS in NYC) have published an impressive overview of systemic lupus erythematosus (SLE) in JAMA. This timely, well-written review covers the many complexities of this multi-organ disorder that affects nearly 3.4 million people worldwide.

Read Article
RheumNow Podcast square

1/600 Falls May Die (4.5.2024)

Jack Cush, MD

Dr. Jack Cush reviews the news and Journal reports from this past week on RheumNow.com -  including problems w/ falls, pain and treatment of Dupuytren’s contractures.

Read Article
#RNL2024 @DrDavidKarp Incomplete lupus is heterogeneous term ""Stage 2"" pre-classification stage as ILE/UCTD Stage 1: non-specific antibodies, dysregulation 2: incomplete features 3: classified, multi-system disease 4: irreversible tissue damage https://t.co/lmorwojG49

Links:

Dr. John Cush RheumNow ( View Tweet)

Urine proteomics in lupus nephritis IL-16 and CD163 are urinary biomarkers most correlated w/ histologic activity Myeloid & degranulation sign ass w histo activity -> PR3+cells abundant in LN @andreafava #RNL2024 @RheumNow https://t.co/YpoMiupOlQ

Links:

Dr. John Cush RheumNow ( View Tweet)

Venous thromboembolic event Risk study in 1854 SLE pts vs controls (12,107) from 1985–2015 in W Australia. VTE affected 12.8% SLE pts; 6 fold higher than controls (RR 6.6). Risk factors: aPL(aHR 4.24), serositis (2.7), nephritis (1.75), low Plts (1.65) https://t.co/KNInhNkjmQ https://t.co/jT3cTemxMD

Links:

Dr. John Cush RheumNow ( View Tweet)
Our final TNR for the month of April will take place on 4/30 at 6:30pm ET. Mastering SLE Rethinking Pre-Clinical Disease in Lupus - David Karp, MD Biology and Rx of Lupus Flares - Michelle Kahlenberg, MD Current/Future Biomarkers in SLE - Andrea Fava, MD https://t.co/IoRDAaAJbo https://t.co/C7HpKvehXX

Links:

Dr. John Cush RheumNow ( View Tweet)
Single center retrospective 173 pts w/ CTD-ILD - 34% Sjogren’s, 30 RA, 25 systemic sclerosis, 6 UCTD, 3% idiopathic inflam myositis, 1,2% MCTD, 0.6% SLE. NSIP most common (60%) inSS & SSc; UIP more common in RA. 6 died, mostly infection https://t.co/IL2tnVDtoQ https://t.co/Ada49Qv5XL

Links:

Dr. John Cush RheumNow ( View Tweet)
Lupus Accelerating Breakthroughs Consortium Partners with FDA https://t.co/GW7Zy72oIZ https://t.co/AGYY8WDKcK

Links:

Dr. John Cush RheumNow ( View Tweet)
JAMA: SLE Review Drs.Siegel & Sammaritano (from HSS in NYC) published an impressive overview of SLE) in JAMA. This timely, well-written review covers the many complexities of this multi-organ disorder that affects nearly 3.4 million people worldwide. https://t.co/byr1hRA6rV https://t.co/wZeIdfTlH0

Links:

Dr. John Cush RheumNow ( View Tweet)
SLE in JAMA (authored by Drs Siegel & Sammaritano at HSS), impressive, full-read review, Covers: - Presentations: skin, Jts, brain, heme, etc - Treatments - Prognosis - Complications: CV, infx, CA - FAQs https://t.co/7WHYK3DgIf https://t.co/pC2MSCpn52

Links:

Dr. John Cush RheumNow ( View Tweet)
Is IL-6 a potential therapeutic target in neuropsychiatric lupus (NPSLE)? Just published in the Journal of Neuroinflammation- Some interesting findings from the Putterman lab in a murine NPSLE model... https://t.co/7yn2o7ZRxS

Links:

chaim putterman ChaimPutterman ( View Tweet)

Polycyclic Aromatic Hydrocarbons Increase Lupus Risk A case-controlled study shows environmental exposure to polycyclic aromatic hydrocarbons (PAH) may increase the risk of developing systemic lupus erythematosus (SLE). https://t.co/04MPWwQlUr https://t.co/iTf6EmKLId

Links:

Dr. John Cush RheumNow ( View Tweet)
10 SLE pts w/ ITP and thrombocytopenia were Rx w/ belimumab IV (age 34.3 ± 14 yrs). Overall response rate of thrombocytopenia was 90%, w/ improvement in platelets, lymphocyte count, Hgb, dsDNA, C3, C4 and SLEDAI https://t.co/5U7mHoY0fg https://t.co/oOqUJqUNgl

Links:

Dr. John Cush RheumNow ( View Tweet)
Neuropsychiatric (NP) Sxs compared in SLE (n 609), controls (463) & IA patients (489). Hallucinations and severe headache were most directly attributable to NP-SLE. https://t.co/JWbyHmpWcq https://t.co/gBubdEjq63

Links:

Dr. John Cush RheumNow ( View Tweet)
How well do you know this week's rheumatology news?
Take the rheumIQ quiz
Take the RheumIQ Quiz

×